Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
| Autor: | Hyun Ae Jung, Jung Yong Hong, Moon Ki Choi, Won Jin Chang, Sung-min Kim, Moon Jin Kim, Keunchil Park, Hye Sook Kim, Jong-Mu Sun, Myung-Ju Ahn |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors medicine.medical_treatment Carcinoma squamous cell Docetaxel Neutropenia Head and neck neoplasms Gastroenterology Drug Administration Schedule Hemato-Oncology 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Retrospective Studies Cisplatin Chemotherapy Squamous Cell Carcinoma of Head and Neck business.industry Combination chemotherapy Middle Aged medicine.disease Head and neck squamous-cell carcinoma Progression-Free Survival Regimen Toxicity Disease Progression Medicine Original Article Female 030211 gastroenterology & hepatology Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | The Korean Journal of Internal Medicine The Korean Journal of Internal Medicine, Vol 34, Iss 5, Pp 1107-1115 (2019) |
| ISSN: | 2005-6648 1226-3303 |
| Popis: | Background/Aims We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Methods In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m2 (day 1 and 8) and cisplatin 70 mg/m2 (day 1) as first-line chemotherapy, repeated every 3 weeks. Results Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality. Conclusions For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|